Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily for 6 Months in Adolescents and Adult Subjects With Stable Patchy Alopecia Areata With Optional Long-Term Open-Label Extension
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2020
Price :
$35
*
At a glance
- Drugs Ifidancitinib (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 20 May 2020 Status changed from active, no longer recruiting to discontinued.
- 30 Jul 2019 Planned End Date changed from 18 Jan 2020 to 13 Sep 2019.
- 26 Jun 2019 According to an Aclaris Therapeutics media release, company will conduct a conference call at 5:00 PM today to review the results of this trial and related matters.The conference call will be webcast live over the Internet and can be accessed by logging on to the Investors page of the company website. To participate on the live call, please dial (844) 776-7782 (domestic) or (661) 378-9535 (international), and reference conference ID 3497800 prior to the start of the call.